Disruption of Fas-Fas Ligand Signaling, Apoptosis, and Innate Immunity by Bacterial Pathogens

1. SudaT, TakahashiT, GolsteinP, NagataS (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169–1178.

2. LocksleyRM, KilleenN, LenardoMJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487–501.

3. StrasserA, JostPJ, NagataS (2009) The many roles of FAS receptor signaling in the immune system. Immunity 30: 180–192.

4. WangL, YangJK, KabaleeswaranV, RiceAJ, CruzAC, et al. (2010) The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol 17: 1324–1329.

5. NagataS (1997) Apoptosis by death factor. Cell 88: 355–365.

6. BoatrightKM, SalvesenGS (2003) Mechanisms of caspase activation. Curr Opin Cell Biol 15: 725–731.

7. EnariM, SakahiraH, YokoyamaH, OkawaK, IwamatsuA, et al. (1998) A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43–50.

8. HensonPM, TuderRM (2008) Apoptosis in the lung: induction, clearance and detection. Am J Physiol Lung Cell Mol Physiol 294: L601–611.

9. CastroJE, ListmanJA, JacobsonBA, WangY, LopezPA, et al. (1996) Fas modulation of apoptosis during negative selection of thymocytes. Immunity 5: 617–627.

10. XerriL, DevilardE, HassounJ, MawasC, BirgF (1997) Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 50: 87–91.

11. HamannKJ, DorscheidDR, KoFD, ConfortiAE, SperlingAI, et al. (1998) Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium. Am J Respir Cell Mol Biol 19: 537–542.

12. AshidaH, MimuroH, OgawaM, KobayashiT, SanadaT, et al. (2011) Cell death and infection: a double-edged sword for host and pathogen survival. J Cell Biol 195: 931–942.

13. LabbeK, SalehM (2008) Cell death in the host response to infection. Cell Death Differ 15: 1339–1349.

14. HagimotoN, KuwanoK, KawasakiM, YoshimiM, KanekoY, et al. (1999) Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am J Respir Cell Mol Biol 21: 436–445.

15. ParkDR, ThomsenAR, FrevertCW, PhamU, SkerrettSJ, et al. (2003) Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol 170: 6209–6216.

16. FarnandAW, EastmanAJ, HerreroR, HansonJF, MongovinS, et al. (2011) Fas activation in alveolar epithelial cells induces KC (CXCL1) release by a MyD88-dependent mechanism. Am J Respir Cell Mol Biol 45: 650–658.

17. TakahashiT, TanakaM, BrannanCI, JenkinsNA, CopelandNG, et al. (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76: 969–976.

18. NagataS (1994) Mutations in the Fas antigen gene in lpr mice. Semin Immunol 6: 3–8.

19. PerlM, ChungCS, PerlU, Lomas-NeiraJ, de PaepeM, et al. (2007) Fas-induced pulmonary apoptosis and inflammation during indirect acute lung injury. Am J Respir Crit Care Med 176: 591–601.

20. PerlM, ChungCS, Lomas-NeiraJ, RachelTM, BifflWL, et al. (2005) Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am J Pathol 167: 1545–1559.

21. GrassmeH, KirschnekS, RiethmuellerJ, RiehleA, von KurthyG, et al. (2000) CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa. Science 290: 527–530.

22. JonesNL, DayAS, JenningsH, ShannonPT, Galindo-MataE, et al. (2002) Enhanced disease severity in Helicobacter pylori-infected mice deficient in Fas signaling. Infect Immun 70: 2591–2597.

23. FanT, LuH, HuH, ShiL, McClartyGA, et al. (1998) Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 187: 487–496.

24. BangaS, GaoP, ShenX, FiscusV, ZongWX, et al. (2007) Legionella pneumophila inhibits macrophage apoptosis by targeting pro-death members of the Bcl2 protein family. Proc Natl Acad Sci U S A 104: 5121–5126.

25. JonesRM, WuH, WentworthC, LuoL, Collier-HyamsL, et al. (2008) Salmonella AvrA coordinates suppression of host immune and apoptotic defenses via JNK pathway blockade. Cell Host Microbe 3: 233–244.

26. CaulfieldAJ, WalkerME, GieldaLM, LathemWW (2014) The Pla protease of Yersinia pestis degrades Fas ligand to manipulate host cell death and inflammation. Cell Host Microbe 15: 424–434.

27. LathemWW, PricePA, MillerVL, GoldmanWE (2007) A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 315: 509–513.

28. BergsbakenT, CooksonBT (2007) Macrophage activation redirects Yersinia-infected host cell death from apoptosis to caspase-1-dependent pyroptosis. PLoS Pathog 3: e161.

29. LathemWW, SchroederJA, BellowsLE, RitzertJT, KooJT, et al. (2014) Posttranscriptional regulation of the Yersinia pestis cyclic AMP receptor protein Crp and impact on virulence. mBio 5: e01038–01013.

30. PhilipNH, BrodskyIE (2012) Cell death programs in Yersinia immunity and pathogenesis. Front Cell Infect Microbiol 2: 149.

31. ZaubermanA, CohenS, MamroudE, FlashnerY, TidharA, et al. (2006) Interaction of Yersinia pestis with macrophages: limitations in YopJ-dependent apoptosis. Infect Immun 74: 3239–3250.

32. BrodskyIE, MedzhitovR (2008) Reduced secretion of YopJ by Yersinia limits in vivo cell death but enhances bacterial virulence. PLoS Pathog 4: e1000067.

33. ZaubermanA, TidharA, LevyY, Bar-HaimE, HalperinG, et al. (2009) Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS ONE 4: e5938.

34. SpinnerJL, SeoKS, O'LoughlinJL, CundiffJA, MinnichSA, et al. (2010) Neutrophils are resistant to Yersinia YopJ/P-induced apoptosis and are protected from ROS-mediated cell death by the type III secretion system. PLoS ONE 5: e9279.

35. NewtonHJ, PearsonJS, BadeaL, KellyM, LucasM, et al. (2010) The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog 6: e1000898.

36. NadlerC, BaruchK, KobiS, MillsE, HavivG, et al. (2010) The type III secretion effector NleE inhibits NF-kappaB activation. PLoS Pathog 6: e1000743.

37. LiS, ZhangL, YaoQ, LiL, DongN, et al. (2013) Pathogen blocks host death receptor signalling by arginine GlcNAcylation of death domains. Nature 501: 242–246.

38. PearsonJS, GioghaC, OngSY, KennedyCL, KellyM, et al. (2013) A type III effector antagonizes death receptor signalling during bacterial gut infection. Nature 501: 247–251.

39. LinkermannA, QianJ, LettauM, KabelitzD, JanssenO (2005) Considering Fas ligand as a target for therapy. Expert Opin Ther Targets 9: 119–134.

40. SteinwedeK, HenkenS, BohlingJ, MausR, UeberbergB, et al. (2012) TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice. J Exp Med 209: 1937–1952.

41. HotchkissRS, NicholsonDW (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nature Rev Immunol 6: 813–822.